Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.68 95% CI 0.49–0.94Authors' conclusion
In this real-world analysis, romosozumab was associated with a significantly lower risk of all-cause mortality compared to teriparatide among patients with osteoporosis.
Study context
- Population
- Patients aged ≥ 20 years diagnosed with osteoporosis 2016–2023, excluding malignancies, bone neoplasms, multiple myeloma, parathyroid disorders or cerebrovascular accidentsmatched cohort
- Participants
- 2,470 vs 2,470
- Exposure
- Romosozumab vs teriparatide
- Romosozumabn = 2,470
- Teriparatiden = 2,470reference
- Outcome
- All-cause mortality
Methodological detailspropensity score-matched (1:1), TriNetX US Collaborative Network, >120 healthcare organizations
- Propensity score-matched (1:1)
- TriNetX US Collaborative Network, >120 healthcare organizations
Main finding
As reported in the abstract
Hazard ratio
0.68
95% CI 0.49–0.94
Romosozumabvs Teriparatide
HR 0.68 (95% CI 0.49–0.94)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality, patients aged ≥ 60 years (subgroup) | 0.65 (0.47–0.88) | |
| 0.512Hazard ratio (log scale) |
All-cause mortality, comorbidity subgroups incl. diabetes mellitus and CKD
- Consistently favoured romosozumab, but did not reach statistical significance
All-cause mortality, patients with hypertension or coronary heart disease
- No increased mortality risk observed
Original publication
Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study. Osteoporos Int. Published 10 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →